Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-17-010837
Filing Date
2017-10-23
Accepted
2017-10-23 16:42:20
Documents
1
Period of Report
2017-10-20

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4101917traversa_relmada.html 4  
1 OWNERSHIP DOCUMENT f4101917traversa_relmada.xml 4 3965
  Complete submission text file 0001213900-17-010837.txt   5401
Mailing Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016
Business Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016 646-677-3853
RELMADA THERAPEUTICS, INC. (Issuer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations

Mailing Address 138 CANTERBURY LN BLUE BELL PA 19422
Business Address
TRAVERSA SERGIO (Reporting) CIK: 0001565832 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-55347 | Film No.: 171149302